|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also found that miR-501-5p could directly target lysophosphatidic acid receptor 1 (LPAR1) and negatively regulate LPAR1 expression in GC cell lines by performing dual-luciferase reporter gene assay and Western blot analysis.
|
31746031 |
2020 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also found that miR-501-5p could directly target lysophosphatidic acid receptor 1 (LPAR1) and negatively regulate LPAR1 expression in GC cell lines by performing dual-luciferase reporter gene assay and Western blot analysis.
|
31746031 |
2020 |
|
Nasopharyngeal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Long noncoding RNA ZFAS1 promotes tumorigenesis and metastasis in nasopharyngeal carcinoma by sponging miR-892b to up-regulate LPAR1 expression.
|
31851778 |
2020 |
|
Refractory anemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Firstly, the expression levels of LPA and lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) in RA patients, osteoarthritis (OA) patients, and healthy controls were detected.
|
31781264 |
2019 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) is in the spotlight because its synthetic antagonist has been under clinical trials for lung fibrosis and psoriasis.
|
31429777 |
2019 |
|
Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.
|
31429784 |
2019 |
|
Anaplastic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of ATX was highest in MC, while the LPA1 expression was higher in PDC and AC, and the expression of LPA2 and LPA3 was highest in PTC (p < 0.001).
|
31455351 |
2019 |
|
Undifferentiated carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of ATX was highest in MC, while the LPA1 expression was higher in PDC and AC, and the expression of LPA2 and LPA3 was highest in PTC (p < 0.001).
|
31455351 |
2019 |
|
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In univariate analysis, ATX positivity (p = 0.005) and LPA1 positivity (p = 0.014) were correlated with shorter overall survival in PTC.
|
31455351 |
2019 |
|
Serous cystadenocarcinoma ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
LPAR1 plays essential roles in the invasion, migration, and proliferation of heterogeneous subsets of OSC cell lines and the development of ITH of OSC, possibly by modulating the activity of the PI3K/AKT signaling pathway.
|
31384176 |
2019 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We did not notice significant changes in the LpA-I concentrations in the following stages of CKD (3a CKD stage: 57 ± 19; 3b CKD stage: 54 ± 15; 4 CKD stage: 52 ± 14; <i>p</i> = 0.49).
|
30857306 |
2019 |
|
Speech Sound Disorders
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, SSd significantly decreased the expression of LPA1 and the degree of neuronal apoptosis in SH-SY5Y cells which were co-cultured with LPS-stimulated BV2 microglia.
|
31145906 |
2019 |
|
Paroxysmal Nonkinesigenic Dyskinesia 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of ATX was highest in MC, while the LPA1 expression was higher in PDC and AC, and the expression of LPA2 and LPA3 was highest in PTC (p < 0.001).
|
31455351 |
2019 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
LPA1 antagonist may be considered as a potential therapeutic and preventative drug for cardiovascular disease.
|
30064908 |
2018 |
|
Caffeine related disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Silymarin and caffeine combination ameliorates experimentally-induced hepatic fibrosis through down-regulation of LPAR1 expression.
|
29477472 |
2018 |
|
Water Stress
|
0.010 |
Biomarker
|
disease |
BEFREE |
Characterization of the Symbiotic Nitrogen-Fixing Common Bean Low Phytic Acid (lpa1) Mutant Response to Water Stress.
|
29462877 |
2018 |
|
High grade serous carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to analyze the expression, biological role and clinical relevance of autotaxin (ATX), the enzyme synthetizing lysophosphatidic acid (LPA), and LPA receptors (LPAR) in high-grade serous carcinoma (HGSC). mRNA expression by qRT-PCR of LPAR1-6 was analyzed in 155 HGSC specimens (88 effusions, 67 solid lesions).
|
30032361 |
2018 |
|
Ligamentum flavum hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lysophosphatidic Acid Induces Ligamentum Flavum Hypertrophy Through the LPAR1/Akt Pathway.
|
29466791 |
2018 |
|
Aortic Valve Stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway.
|
28472283 |
2017 |
|
Bronchopulmonary Dysplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> LPAR1-deficient rats have increased hyperoxia-induced BPD survival rates and, despite the presence of neonatal emphysema, are less sensitive to an aggravated "second hit" than Wistar controls with BPD.
|
28382003 |
2017 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease.
|
27169356 |
2017 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease.
|
27169356 |
2017 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast, siLPA1-MSCs showed resistance to cellular senescence in vitro, and efficiently delayed progression of MM and tumor-related angiogenesis in vivo.
|
27641212 |
2017 |
|
Spinal stenosis of lumbar region
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hypertrophy and Fibrosis of the Ligamentum Flavum in Lumbar Spinal Stenosis is Associated With Increased Expression of LPA and LPAR1.
|
28323698 |
2017 |
|
Endometriosis of uterus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LPA1, LPA4 and LPA5 immunoreactivity were significantly higher in the adenomyosis group than in the control group, while LPA2 and LPA3 immunoreactivity were significantly lower in the adenomyosis group than in the control group.
|
29178922 |
2017 |